Veraxa Biotech AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| J8L0.F | HURA | MGNX | CTMX | STRO | PYXS | |
|---|---|---|---|---|---|---|
| Market cap | 118.08M | 109.61M | 147.15M | 512.06M | 164.82M | 198.30M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -2.8 | -1.6 | -5.0 | -1.6 | -1.5 |
| Price/book | -0.7 | 6.0 | 3.4 | 1.7 | -1.6 | 9.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −74.12% | −29.80% | +61.81% | −43.91% | −2.96% | −58.91% |
| Today | 0.00% | +3.93% | −0.86% | +7.80% | +4.52% | +1.22% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All J8L0.F news ›VERAXA Biotech AG And OmniAb, Inc. Advance Bispecific Antibody Drug Conjugate Program VXA-222 From Joint Discovery Collaboration
VERAXA Biotech AG announced the advancement of bispecific ADC program VXA-222, following successful achievement of a key technical milestone in its alliance with OmniAb, Inc. The program is moving... VERAXA Biotech AG announced the…
Veraxa Biotech Advances Bispecific Antibody Drug Conjugate Program
Veraxa Biotech is advancing the VXA-222 bispecific antibody drug conjugate program, a joint discovery collaboration with OmniAb , after achieving a key technical milestone, the company said... Biotechnology & Medical Research Veraxa…
VERAXA Biotech AG (NASDAQ: VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is expanding its use of human-relevant testing methods across its oncology research programs, seeking to generate more clinically informative…
VERAXA Biotech’s Dual-Targeting Strategy Aims to Sharpen Cancer Therapy Precision
citybuzz - VERAXA Biotech (NASDAQ: VRXA) is developing antibody-based cancer therapies designed to improve treatment selectivity and potentially reduce toxicity to healthy tissues, according to a recent BioMedWire news
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
Strengthened financial position with $27.5 million principal amount senior secured note financing and $50 million share purchase agreement to advance VERAXA’s pipeline of oncology drug candidates utilizing its novel BiTAC platform VERAXA…
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY,…
VERAXA Biotech (VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress
LOS ANGELES, CA - October 13, 2026 (NEWMEDIAWIRE) - VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its…
VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing
VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on ... VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing VERAXA Biotech (NASDAQ: VRXA), a…
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
ZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-... VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models…
VERAXA Biotech (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officer
VERAXA Biotech (NASDAQ: VRXA) a developer of next-generation antibody-based cancer therapies, announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener ... VERAXA Biotech (NASDAQ: VRXA) Appoints…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com6
- investors.veraxa.com3
- manilatimes.net2
- marketscreener.com2
- tradingview.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 17 articles, not a forecast.